

~~INACTIVATED VIBRIO CHOLERA VACCINE IN TABLETS~~

Claims

What we claim is:

1. (Currently Amended) A vaccine composition for cholera ~~composed of comprising:~~
 - a. ~~Inactivated~~ inactivated cells of Vibrio cholera;
 - b. an agglutinant; Agglutinants
 - c. Lubricants a lubricant;
 - d. Coating a coating substance;
 - e. Filling a filling substance; and
 - f. Disintegrating a disintegrating substance
2. (Currently Amended) The vaccine composition ~~described in~~ of Claim 1, with said inactivated cells consisting of attenuated strains of Vibrio cholerae.
3. (Currently Amended) The vaccine composition ~~described in~~ of Claim 2, with said inactivated cells belonging to the serum group O139.
4. (Currently Amended) The vaccine composition ~~described in~~ of Claim 3, with said inactivated cells belonging to the serum group O1.

5. (Currently Amended) The vaccine composition described in of Claim 4, with further comprising El Tor or Classic type cells.
6. (Currently Amended) The vaccine composition described in of Claim 5, the said inactivated cells belonging to the Ogawa or Inaba serum type.
7. (Currently Amended) The vaccine composition described in of Claim 2, the said inactivated cells consisting of wild strains of Vibrio cholerae.
8. (Currently Amended) The vaccine composition described in of Claim 7, the said inactivated cells belonging to the serum group O139.
9. (Currently Amended) The vaccine composition described in of Claim 8, the said inactivated cells belonging to the serum group O1.
10. (Currently Amended) The vaccine composition described in of Claim 9, with further comprising El Tor or Classic bio-type cells.
11. (Currently Amended) The vaccine composition described in of Claim 10, with further comprising Ogawa or Inaba serum type cells
12. (Currently Amended) The vaccine composition described in of Claims 1 to 11 Claim 7, containing said vaccine composition being in the form of an oral administration unit, said unit between 5×10^9 and 10^{11} of said inactivated cells per tablet unit.
13. (Currently Amended) The vaccine composition described in of Claim 1, with said agglutinant being at least one selected from povidone, gelatin, or and carboxymethylcellulose as an agglutinant.

14. (Currently Amended) The vaccine composition described in of Claim 13, with the agglutinants found at being in a concentration of between 1 and 5% by weight of the tablet's total mass of the unit.

15. (Currently Amended) The vaccine composition described in of Claim 1, with said lubricant being at least one selected from sodium carboxymethylstarch, magnesium stearate, silicon dioxide, or and talc as a lubricants.

16. (Currently Amended) The vaccine composition described in of Claim 12, the lubricants found at being in a concentration between 0.25 and 1.5% by weight of the tablet's total mass of the unit.

17. (Currently Amended) The vaccine composition described in of Claim 1, with said coating substance being at least one selected from cellulose acetophthalate, cellulose diethylphthalate, lacquer at 10% or and titanium dioxide as a coating substance.

18. (Currently Amended) The vaccine composition described in of Claim 12, with said coating substance found at a being in concentration between 1 and 2% by weight of the tablet's total mass of the unit.

19. (Currently Amended) The vaccine composition described in of Claim 1, with said filling substance being at least one selected from lactose or and cornstarch as filling substance.

20. (Currently Amended) The vaccine composition described in of Claim 19 12, the filling substance found at being in a concentration between 65 and 80% that of tablet's total the mass of the unit.

21. (Currently Amended) The vaccine composition described in of Claim 1, with said disintegrating substance being at lease one selected from sodium croscarmelose, cornstarch or and micro-crystalline cellulose as a disintegrating substance.

22. (Currently Amended) The vaccine composition described in of Claim 24 12, the disintegrating substance found at being in a concentration of between 1 and 6% by weight that of the tablet's total mass of the unit.

23. (New) The vaccine composition of claim 12, said oral administration unit comprises a tablet.

24. (New) The vaccine composition of claim 1, said composition being formed into a tablet for oral administration of the vaccine for cholera.

25. (New) A vaccine composition for cholorea comprising an oral administrating unit comprising inactivated cells of vibrio cholera.

26. (New) The vaccine of claim 25, said cells comprises whole cells.